RETAVASE® (reteplase) is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin degrades the fibrin matrix of the thrombus, exerting its thrombolytic action.
Proven efficacy in acute STEMI1‑3
![](https://retavase.com/wp-content/themes/html5blank-stable/img/hr.jpg)
More patients achieved TIMI 2 or 3 flow at 90 minutes with RETAVASE® (reteplase) in the RAPID studies compared with alteplase1-3
Two clinical studies compared patency rates 90 minutes after treatment with RETAVASE or two different regimens of alteplase in patients with acute STEMI. Partial or complete flow (TIMI grades 2 or 3) and complete flow (TIMI grade 3) were reported.
Coronary artery patency: Angiographic results1
*P value represents one of multiple dose comparisons.
- The relationship between coronary artery patency and clinical efficacy has not been established1
- Reocclusion rates for RETAVASE and alteplase were similar in both studies1-3
RAPID 2: Percentage of patients with total patency or complete reperfusion of infarct-related artery over time2
†Only the primary endpoint, the 90-minute assessment, was mandatory according to trial protocol.
RAPID 1: Percentage of patients with partial patency or complete reperfusion of infarct-related artery over time3
†Only the primary endpoint, the 90-minute assessment, was mandatory according to trial protocol.
Study design
‡Represents the number of patients in the 10 + 10 RETAVASE arm plus the alteplase arm. The total number of patients enrolled in RAPID 1 was 606.